ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.164 SNIP: 0.041 CiteScore™: 0.18

ISSN 印刷: 2151-8017
ISSN オンライン: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2014008368
pages 219-239

Bacterial Toxins in Cancer Immunotherapy

Irena Adkins
Sotio a.s., Prague, Czech Republic; and Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
Lenka Sadilkova
Sotio a.s., Prague, Czech Republic; and Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
Lenka Palova-Jelinkova
Sotio a.s., Prague, Czech Republic; and Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

要約

Bacterial protein toxins perfected through evolution in pathogenic bacteria play an important role in infectious diseases and share the ability to target various intracellular proteins to modulate host immune responses. Several bacterial toxins and their nontoxic mutants have been intensively studied over the past decades to harness their abilities to enter host cells and deliver drugs for a direct elimination of cancer cells, to carry antigenic epitopes to stimulate adaptive T cell responses, and to boost immunity as adjuvants. Some of these toxins may be utilized in the diagnostics of cancer. Whereas the immunotherapeutic potential of some bacterial toxins is currently being evaluated in various phases of clinical cancer trials, the medical use of others needs to be further established. The major achievement in toxin-targeted immunotherapy is a derivative of lipopolysaccharide monophosphoryl lipid A, muramyl dipeptide derivative Mifamurtide, and Corynebacterium diphtheriae diphtheria toxin-based immunotoxin denileukin diftitox. However, some limitations of the use of bacterial toxins in human immunotherapy remain to be overcome.


Articles with similar content:

Stealth Engineering for In Vivo Drug Delivery Systems
Critical Reviews™ in Biomedical Engineering, Vol.43, 2015, issue 5-6
Ankita Mohapatra, Richard A. Smith, Bashir I. Morshed, Warren O. Haggard
Novel Strategies Using DNA for the Induction of Mucosal Immunity
Critical Reviews™ in Immunology, Vol.19, 1999, issue 4
Heather L. Davis, Michael J. McCluskie
Mycobacterium Biofilms: Factors Involved in Development, Dispersal, and Therapeutic Strategies Against Biofilm-Relevant Pathogens
Critical Reviews™ in Eukaryotic Gene Expression, Vol.24, 2014, issue 3
Jianping Xie, Wanyan Deng, Xiaohong Xiang, Minqiang Liu
Cationic Antimicrobial Peptides and Their Multifunctional Role in the Immune System
Critical Reviews™ in Immunology, Vol.20, 2000, issue 5
Robert E. W. Hancock, Monisha G. Scott
Mucosal Immunization: A Review of Strategies and Challenges
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 4
Mohan N. Rathi, Hinal Patel, Chetan Yewale, Ambikanandan Misra